NR4A1 and ductal breast carcinoma in situ: There were 1527 (10.0%; range: 0–24%; median: 0%) patients with ductal carcinoma in situ (DCIS) and 12640 participants with hormone receptor positive disease included (82.7%; range: 56–96%; median: 88.8%).